Breaking Finance News

Merck KGaA(ADR) (NASDAQ:MKGAY) has been upgraded to Buy in a statement by Bank of America Corp. earlier today.

Bank of America Corp. has upgraded Merck KGaA(ADR) (NASDAQ:MKGAY) to Buy in a statement released on Friday October 14, 2016.

Having a price of $35.23, Merck KGaA(ADR) (NASDAQ:MKGAY) traded 0.57% higher on the day. With the last close up 4.96% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Merck KGaA(ADR) has recorded a 50-day average of $35.69 and a two hundred day average of $33.57. Volume of trade was down over the average, with 2,587 shares of MKGAY changing hands under the typical 5,446

Performance Chart

Merck KGaA(ADR) (NASDAQ:MKGAY)

With a total market value of $0, Merck KGaA(ADR) has price-earnings ratio of 29.72 with a one year low of $26.91 and a one year high of $37.16 .

More About Merck KGaA(ADR) (NASDAQ:MKGAY)

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ) and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.